442 related articles for article (PubMed ID: 23705946)
21. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
22. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
[TBL] [Abstract][Full Text] [Related]
23. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
[TBL] [Abstract][Full Text] [Related]
24. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
[TBL] [Abstract][Full Text] [Related]
25. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
26. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
27. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
[TBL] [Abstract][Full Text] [Related]
28. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
29. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
30. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice.
Starenki D; Singh NK; Jensen DR; Peterson FC; Park JI
Cancer Lett; 2013 Oct; 339(1):144-51. PubMed ID: 23856028
[TBL] [Abstract][Full Text] [Related]
31. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
32. Cabozantinib in Thyroid Cancer.
Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
[TBL] [Abstract][Full Text] [Related]
33. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
[TBL] [Abstract][Full Text] [Related]
34. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
35. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
Hoy SM
Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
[TBL] [Abstract][Full Text] [Related]
37. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
38. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract][Full Text] [Related]
39. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2.
Grüllich C
Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
